SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sandu Pharmaceuticals trades higher on getting nod to incorporate wholly owned subsidiary

15 Feb 2022 Evaluate

Sandu Pharmaceuticals is currently trading at Rs. 58.65, up by 1.10 points or 1.91% from its previous closing of Rs. 57.55 on the BSE.

The scrip opened at Rs. 61.90 and has touched a high and low of Rs. 61.90 and Rs. 56.50 respectively. So far 5193 shares were traded on the counter.

The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 75.90 on 03-Jan-2022 and a 52 week low of Rs. 27.45 on 22-Mar-2021.

Last one week high and low of the scrip stood at Rs. 65.50 and Rs. 55.00 respectively. The current market cap of the company is Rs. 47.41 crore.

The promoters holding in the company stood at 48.02%, while Institutions and Non-Institutions held 0.01% and 51.97% respectively.

Sandu Pharmaceuticals’ board has approved incorporation of a wholly owned subsidiary of the company namely ‘Sandu Phytoceuticals’. The proposed wholly owned subsidiary company to be incorporated in India shall carry out business in the field of Pharmaceuticals/ Phytoceuticals Products. The incorporation of the wholly owned subsidiary will leverage the growth opportunities and will help the company in becoming more broad based and focused. The Board of Director of the company in its meeting held on February 14, 2022 has approved the same. 

Sandu Pharmaceuticals, popularly called by people Sandu Ayurveda, is one of the renewed brands when it's come to Ayurvedic health care Products or Medicines.


Sandu Pharmaceutical Share Price

38.45 0.50 (1.32%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×